Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Neuroophthalmol ; 42(2): 251-255, 2022 06 01.
Article in English | MEDLINE | ID: covidwho-1596393

ABSTRACT

BACKGROUND: The opsoclonus-myoclonus-ataxia syndrome (OMAS) represents a pathophysiology and diagnostic challenge. Although the diverse etiologies likely share a common mechanism to generate ocular, trunk, and limb movements, the underlying cause may be a paraneoplastic syndrome, as the first sign of cancer, or may be a postinfectious complication, and thus, the outcome depends on identifying the trigger mechanism. A recent hypothesis suggests increased GABAA receptor sensitivity in the olivary-oculomotor vermis-fastigial nucleus-premotor saccade burst neuron circuit in the brainstem. Therefore, OMAS management will focus on immunosuppression and modulation of GABAA hypersensitivity with benzodiazepines. METHODS: We serially video recorded the eye movements at the bedside of 1 patient with SARS-CoV-2-specific Immunoglobulin G (IgG) serum antibodies, but twice-negative nasopharyngeal reverse transcription polymerase chain reaction (RT-PCR). We tested cerebrospinal fluid (CSF), serum, and nasopharyngeal samples. After brain MRI and chest, abdomen, and pelvis CT scans, we treated our patient with clonazepam and high-dose Solu-MEDROL, followed by a rituximab infusion after her formal eye movement analysis 10 days later. RESULTS: The recordings throughout her acute illness demonstrated different eye movement abnormalities. While on high-dose steroids and clonazepam, she initially had macrosaccadic oscillations, followed by brief ocular flutter during convergence the next day; after 10 days, she had bursts of opsoclonus during scotopic conditions with fixation block but otherwise normal eye movements. Concern for a suboptimal response to high-dose Solu-MEDROL motivated an infusion of rituximab, which induced remission. An investigation for a paraneoplastic etiology was negative. CSF testing showed elevated neuron-specific enolase. Serum IgG to Serum SARS-CoV2 IgG was elevated with negative RT-PCR nasopharyngeal testing. CONCLUSION: A recent simulation model of macrosaccadic oscillations and OMAS proposes a combined pathology of brainstem and cerebellar because of increased GABAA receptor sensitivity. In this case report, we report 1 patient with elevated CSF neuronal specific enolase, macrosaccadic oscillations, ocular flutter, and OMAS as a SARS-CoV-2 postinfectious complication. Opsoclonus emerged predominantly with fixation block and suppressed with fixation, providing support to modern theories on the mechanism responsible for these ocular oscillations involving cerebellar-brainstem pathogenesis.


Subject(s)
COVID-19 , Cerebellar Ataxia , Ocular Motility Disorders , Opsoclonus-Myoclonus Syndrome , COVID-19/complications , Cerebellar Ataxia/complications , Clonazepam/therapeutic use , Female , Humans , Immunoglobulin G , Methylprednisolone Hemisuccinate/therapeutic use , Ocular Motility Disorders/diagnosis , Ocular Motility Disorders/drug therapy , Ocular Motility Disorders/etiology , Opsoclonus-Myoclonus Syndrome/diagnosis , Opsoclonus-Myoclonus Syndrome/drug therapy , Opsoclonus-Myoclonus Syndrome/etiology , RNA, Viral/therapeutic use , Receptors, GABA-A/therapeutic use , Rituximab/therapeutic use , SARS-CoV-2
2.
BMJ Case Rep ; 14(3)2021 Mar 18.
Article in English | MEDLINE | ID: covidwho-1143021

ABSTRACT

COVID-19 and granulomatosis with polyangiitis share many clinical and radiological features, making it challenging for clinicians to distinguish between the two. In this case report, we describe a patient who was diagnosed with COVID-19 in October 2020. One month later, she presented with persistent fatigue, shortness of breath and anaemia with worsening renal functions, found to have elevated antineutrophil cytoplasmic antibodies and antiproteinase 3 antibodies, and diagnosed with granulomatosis with polyangiitis.


Subject(s)
COVID-19/complications , Granulomatosis with Polyangiitis/diagnosis , Granulomatosis with Polyangiitis/etiology , Anti-Inflammatory Agents/therapeutic use , Biopsy , Diagnosis, Differential , Female , Granulomatosis with Polyangiitis/drug therapy , Humans , Immunologic Factors/therapeutic use , Kidney/pathology , Methylprednisolone Hemisuccinate/therapeutic use , Middle Aged , Rituximab/therapeutic use , SARS-CoV-2
3.
BMJ Case Rep ; 13(11)2020 Oct 13.
Article in English | MEDLINE | ID: covidwho-860668

ABSTRACT

Sudden onset sensorineural hearing loss (SSNHL) is frequently seen by otolaryngologists. The exact pathophysiology of the disease is still unknown, with the most likely causative factor being following a viral infection. Immediate steroids are the best treatment to improve prognosis. Despite a plethora of papers in the literature describing SSNHL, there are only a few reported cases of hearing loss following COVID-19, none of which have been reported in the UK. This paper presents the first UK case of SSNHL following COVID-19. Physical examination and imaging excluded any other cause of hearing loss. A literature review showed that four other cases have been previously described. Hearing loss can be a significant cause of morbidity and can easily be missed in the intensive care setting. Being aware and screening for SSNHL following COVID-19 enables an early course of steroids, which offers the best chance of recovering hearing.


Subject(s)
Betacoronavirus , Coronavirus Infections/complications , Hearing Loss, Sudden/complications , Hearing Loss, Sudden/drug therapy , Methylprednisolone Hemisuccinate/therapeutic use , Pneumonia, Viral/complications , Prednisolone/therapeutic use , Administration, Oral , COVID-19 , Glucocorticoids/administration & dosage , Glucocorticoids/therapeutic use , Hearing Loss, Sudden/diagnosis , Humans , Injections , Male , Methylprednisolone Hemisuccinate/administration & dosage , Middle Aged , Pandemics , Prednisolone/administration & dosage , SARS-CoV-2
4.
Emerg Infect Dis ; 26(8): 1941-1943, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-155428

ABSTRACT

We report 3 patients with coronavirus disease who had a decline in respiratory status during their hospital course that responded well to intravenous steroids and interleukin-6 receptor antagonist therapy. These patients later showed development of persistent hypoxia with increased levels of d-dimer levels and were given a diagnosis of pulmonary embolisms.


Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/complications , Cytokine Release Syndrome/complications , Fibrin Fibrinogen Degradation Products/metabolism , Hypoxia/complications , Pneumonia, Viral/complications , Pulmonary Embolism/complications , Acute Disease , Aged , Antibodies, Monoclonal, Humanized/therapeutic use , Anticoagulants/therapeutic use , Betacoronavirus/drug effects , Betacoronavirus/physiology , Biomarkers/blood , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques/methods , Coronavirus Infections/diagnosis , Coronavirus Infections/drug therapy , Coronavirus Infections/virology , Cytokine Release Syndrome/diagnosis , Cytokine Release Syndrome/drug therapy , Cytokine Release Syndrome/virology , Enoxaparin/therapeutic use , Female , Humans , Hypoxia/diagnosis , Hypoxia/drug therapy , Hypoxia/virology , Male , Methylprednisolone Hemisuccinate/therapeutic use , Middle Aged , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/drug therapy , Pneumonia, Viral/virology , Pulmonary Embolism/diagnosis , Pulmonary Embolism/drug therapy , Pulmonary Embolism/virology , Rivaroxaban/therapeutic use , SARS-CoV-2 , Tomography, X-Ray Computed , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL